Navigation Links


body at medicine technology

Halozyme Therapeutics' Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society

...orsubcutaneous fluid replacement. Although a large body of clinicalexperience supports the benefits and safety of using hyaluronidaseas an adjuvant to increase the absorption and dispersion ofco-injected small molecule drugs, to Halozyme's knowledge, this wasthe first clinical trial conducted to support t...

Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology

...technology for the delivery of drugs into thehuman body through the oral cavity (with no deposit in the lu...yadministered by injection to be absorbed into the body by thelining of the inner mouth using the Company's proprietaryRapidMist(tm) device. The Company's f...

AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis

...s expressed invarious tissues throughout the human body including the kidney andGI tract. AP has been shown to dephosphorylate lipopolysaccharidesto a non-toxic form that acts as a partial antagonist on thelipopolysaccharide receptor complex. In addition tolipopolysaccharides, AP can dephosphorylate diffe...

Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis

...tinto the upper respiratory passages and cause the body to produceantibodies and release histamine. Histamine makes the upperrespiratory membranes swell and produce typical allergy symptomssuch as sneezing, runny nose and nasal congestion. In the U.S.,approximately 50 million people suffer from seasonal a...

New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV

..."This is exciting new information that adds to the body ofknowledge on PREZISTA in a much broader group of...ot be made. Redistribution and/or accumulation of body fat have beenobserved in patients receiving ARV therapy. The causalrelationship, mechanism, and long...

DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC

...ory ABiothreat by the CDC. The toxin can enter the body very efficientlythrough lung tissue and through the gastrointestinal tract, makingthe threat of purposeful food contamination with botulinum toxin areal possibility as a biological weapon. Because the toxin rapidlyenters target neural cells, exposure...

DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC

...ory A Biothreat bythe CDC. The toxin can enter the body very efficiently through lungtissue and through the gastrointestinal tract, making the threat ofpurposeful food contamination a real possibility for use of thetoxin as a biological weapon. Because the toxin rapidly enterstarget neural cells, exposure...

Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company

...ects are counted equally.However, there is a large body of published literature withconvincing evidence that CellCept is better tolerated, and, moreimportantly to patients and their doctors, is associated with fewerserious or life-threatening infections, and hospitalizations. IVCis also linked to a high i...

Aspreva and Roche Announce Preliminary Results for Phase III Study Evaluating CellCept in Lupus Nephritis

...us, is achronic autoimmune disease that causes the body to attack its owntissues and joints. Lupus nephritis, considered life-threatening,but rare, is the most serious manifestation of SLE. If leftuntreated, it can lead to kidney failure, need of dialysis, andpotentially death. It is a complicated disease...

CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS

...rial, including the ALSFRS-R,vital capacity, total body weight and body mass index (a measure ofobesity). In the absence of placebo control, CytRx chose to comparethe open-...

Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer

...cedstages. Lung cancer frequently spreads to other body parts,including the brain. Xcytrin in Second-Line Lung Cancer Pharmacyclics is developing Xcytrin as an anti-cancer agent witha novel mechanism of action that is designed to selectivelyconcentrate in tumors and induce apoptosis (programmed cell dea...

Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone

...vated glucose levels, such as progressivedamage to body organs like the kidneys, eyes, cardiovascularsyste... by affecting the action ofnatural hormones in the body called incretins. Incretins decreaseblood sugar by increasing consumption of sugar by the body, main...

Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone

...vated glucose levels, such as progressivedamage to body organs like the kidneys, eyes, cardiovascularsyste... by affectingthe action of natural hormones in the body called incretins. Incretins decrease blood sugar by increasing consumption of sugarby the body, main...

An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes

...et betacell function determines the ability of the body to produceinsulin, a hormone which plays a central...ptidase-4(DPP-4) inhibitor that enhances a natural body system, called theincretin system, which helps to regulate glucose by affecting thebeta cells and al...

Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis

...ng,tearing, itching, pain, sticky eyelids, foreign body sensation,mucus discharge and photophobia) was superior to the vehicle forboth concentrations of Vekacia(R). For objective signs(conjunctival erythema/hyperhemia, conjunctival chemosis anddischarge, papillae, limbal infiltrates and corneal epithelial...

First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes

...eexcretion at doses ranging from 0.01-1.0 mg/kg of body weightwithout inducing hypoglycemia. Additionally,...vated glucose levels, such as progressivedamage to body organs like the kidneys, eyes, cardiovascularsystem, and nerves. The A1C test gives a picture of the...

New Poll Shows Men, Women Incorrectly Blame Symptoms of Low Testosterone on Normal Aging

...gonadism can include incomplete sexualdevelopment, body hair loss, reduced muscle bulk and increased bodyfat, height loss, low bone density and impaired sperm production.Symptoms associated with hypogonadism can include reduced sexualdesire, depression, changes in mood, poor concentration, decreasedenergy...

Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target

... subjects (average BMI23.9) no relevant changes in body weight or major or minorhypoglycemic events occurr...tide-1(GLP-1), which is rapidly broken down in the body and thus notpractical as a therapy for type 2 diabetes. GLP-1 is released fromthe gastrointestinal t...

Second Phase III Study Evaluating Gilead's Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint

...th and future fracture risk are unknown. Changesin body fat have been observed in patients taking anti-HIVmedicines. The cause and long-term health effect of these changesare unknown. Immune Reconstitution Syndrome has been reported inpatients treated with combination therapy, including Viread. The most ...

Phase IIIb Clinical Data Validate the Overall and Cardiovascular Safety Profile of Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) in Patients with Type 2 Diabetes

..., while maintainingbody fat neutrality or inducing body fat reduction. Cycloset(TM) is currently under investigation as a potentialtherapy for type 2 diabetes and has been studied in several PhaseII and three Phase III studies. An NDA for the drug's use in thetreatment of type 2 diabetes has received an ...

Byetta Treatment for Three and a Half Years Associated with Reductions in Cardiovascular Risk Factors in People with Type 2 Diabetes

... may reduce appetite, the amount of foodeaten, and body weight. These are not all the side effects withBYETTA. A healthcare provider should be consulted about any sideeffect that is bothersome or does not go away. For complete safety profile and other important prescribingconsiderations, visit <a tar...

Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes

...ptidase-4(DPP-4) inhibitor that enhances a natural body system, called theincretin system, which helps to ...mbination with sulfonylurea agents. After 24weeks, body weight was increased more with JANUVIA than withplacebo (mean change from baseline of +0.8 vs. -0.4 ...

Second Phase III Study Evaluating Gilead's Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint

...th and future fracture risk are unknown. Changesin body fat have been observed in patients taking anti-HIVmedicines. The cause and long-term health effect of these changesare unknown. Immune Reconstitution Syndrome has been reported inpatients treated with combination therapy, including Viread. The most ...

Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Association's Annual Meeting

...of beneficialmetabolic effects, notably decreasing body weight, improvements inblood glucose and insulin l...st-treated mice on a high-fat dietshowed decreased body weight, as well as improved glucose andinsulin control compared to the mice treated with vehicle. In...

Elixir Pharmaceuticals Announces Clinical Data at American Diabetes Association Conference Highlighting Ability of Glufast to Maintain Glycemic Control in Patients with Type 2 Diabetes

...n receptor.Elixir has demonstrated EX-1350 reduces body weight by 10 percentat 28-56 days without significant decreases in food intake in ananimal model made insulin resistant and obese after three months ona 60 percent fat diet. The majority of the weight loss is observedin white adipose tissue, with spa...

Infertile Voice Supports Stem Cell Research: RESOLVE Calls for Patient Options in Using Frozen Embryos

... very personal decision aboutthe uses of their own body tissues, including reproductive tissuesand fertilized reproductive tissues," said Collura. Founded in 1974, RESOLVE: The National Infertility Association,headquartered in Bethesda, MD, is the oldest and largestconsumer-based, nonprofit group that pr...

Fact Sheet: Advancing Stem Cell Research While Respecting Moral Boundaries

...p into nearly all the cell types and tissues inthe body - without endangering human life in the process. Byexpanding support for non-destructive research methods, thisExecutive Order will make it more likely that these excitingadvances continue to unfold. -- President Bush Also Vetoed A Bill That Would Ov...

Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinson's Disease

... were observed primarily on thetreated side of the body beginning three months after the genetherapy procedure and persisted through the 12 months formal studyperiod. Neurologix sponsored the study as part of its ongoing efforts todevelop this and other gene therapy approaches to the treatment ofneurod...

MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions

...geting insulin resistance, acondition in which the body does not efficiently use the insulin itproduces to control blood glucose levels. ACTOS is taken once dailyas an adjunct to diet and exercise, and is approved for use fortype 2 diabetes as monotherapy to lower blood glucose and incombination therapy w...

ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting

...-DAC(TM):Exendin-4 or placebo, a mean reduction in body weight of 2.5 kg (vs. 1.2 kg for placebo) was observed at the endof the 3-week in-clinic stay on a controlled diet. Nosignificant safety or tolerability issues were reported atdose levels up to 3 mg. Abstracts for the event can be found on th...

New Study Shows That telmisartan has Greater Renoprotective Potential Thanlosartan in Hypertensive Patients With Type 2 Diabetes

... the dose oftelmisartan to be eliminated from the body compared to fiveto 15 hours for other ARBs.(7,8) Telmisartan is 99.5% boundto serum protein and is excreted almost entirely vianon-renal pathways. Clinical trials have shown thattelmisartan provides powerful and consistent blood pressurereduction ...

Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics

... treatment forALS. "Trophos is proud to have this body of work accepted forpublication in a well recognized journal such as JPET," saidRebecca Pruss, CSO at Trophos. "Given the significant unmet medicalneed in ALS, it is tremendously encouraging that TRO19622 promotesthe survival of motor neurons in this...

Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study

...ls. Various degenerativeconditions associated with body wasting (cachexia) such as cancer,HIV-AIDS and chronic inflammation are potential disease targets forAVR118 therapy. Note: This news release contains forward-looking statements thatinvolve risks associated with clinical development, regulatoryapprov...

Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur

... concentration, which is a counter-reaction of the body potentially decreasing theefficacy of current drug...tensinII. Angiotensin II is a small peptide in the body and part of theso-called renin-angiotensin system (RAS), an important regulator ofblood pressure. An...

Solstice Neurosciences Presents Escalating Dose Study at International Congress in Istanbul, Turkey

...lts reported by Dr. Pappert add to theever-growing body of evidence that MYOBLOC can safely andeffectively be used in a variety of CD patients for the pain andabnormal head position associated with this devastating anddisabling condition." About The Movement Disorder Society Founded in 1985, The Movemen...

Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy

...uding an infection that is in only one place ofthe body (such as an open cut or sore) or an infection that is inthe whole body (such as the flu). Having an infection couldincrease the risk for serious side effects from ORENCIA....

Barrier Therapeutics Announces Liarozole Phase 2/3 Study Results in Lamellar Ichthyosis

...acterized by a thickscaling of the skin over large body areas. Study results showedliarozole, dosed at 75 ...olizing blocking agents (RAMBAs),which inhibit the body from breaking down its own retinoic acid,the active form of vitamin A, a key nutrient for healthy sk...

Study Demonstrated Rozerem (ramelteon) Does Not Affect Middle-of-the-Night Balance in Older Adults with Insomnia

...ntedtoday demonstrated that Rozerem did not affect body sway at peakplasma levels, nor did it impair middl...d near-peak plasmalevels, the effect of ROZEREM on body sway was no different fromplacebo. However, the positive control, zopiclone, did show astatistically...

Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus

...reatmenttoday. This provides us with a substantial body of data on thelong-term effects of LymphoStat-B." About the Phase 2 Trial Results The primary objectives of the Phase 2 study were to evaluate thesafety, tolerability and efficacy of LymphoStat-B plus standard ofcare, versus placebo plus standard o...

Enbrel Safety Data for up to Eight Years in Patients with Juvenile Rheumatoid Arthritis Being Presented at EULAR

... bodies. ENBREL can reducethe amount of TNF in the body to normal levels, helping to treatyour disease. But, in doing so, ENBREL can also lower the abilityof your immune system to fight infections. All medicines have side effects, including ENBREL. Possible sideeffects of ENBREL include: -0- -- Serious ...

July Issue of Journal of Antimicrobial Chemotherapy Highlights Study of Factive Tablets for Five-Day Treatment of Community-Acquired Pneumonia

...e. "The publication ofthese data are adding to the body of scientific evidence thatdemonstrates the importance of short courses of potent antibiotictherapy in treating community-acquired pneumonia, as recommended inthe CAP treatment guidelines from the Infectious Diseases Societyof America and the America...

NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans

...s known as angiogenesis, isa normal process in the body that is essential for organ growth andrepair. In m...alsocritical for normal blood vessel growth in the body -- for example,during menstruation, pregnancy, or tissue repair. Thus, drugs thattarget critical ang...

Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits

...s compared tomorphine and other opiates. The large body of statisticallysignificant Phase III efficacy and side effect/safety data alsosuggest that M6G could be uniquely positioned as an opiateanalgesic for day case surgery - an additional growing market tothe current focus on hospital based post-operativ...

Phase III Study Evaluating Gilead's Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint

...th and future fracture risk are unknown. Changesin body fat have been observed in patients taking anti-HIVmedicines. The cause and long-term health effect of these changesare unknown. Immune Reconstitution Syndrome has been reported inpatients treated with combination therapy, including Viread. The most ...

Human Genome Sciences Announces Positive Final Results Of Phase 2b Trial of Albuferon

...irculatory system, persistingin circulation in the body for over twenty days. Research has shownthat genetic fusion of therapeutic proteins to human albumindecreases clearance and prolongs the half-life of the proteins.Recombinant interferon alpha is approved for the treatment ofhepatitis C, hepatitis B a...

Archimedes Pharma Presents Positive Efficacy and Safety Data on Nasalfent at European Association for Palliative Care Congress

...now underway, Archimedes isgenerating an extensive body of data to support regulatory filingsin both the US and Europe with the aim of bringing a vital therapyto patients with breakthrough cancer pain." Nasalfent is a trade mark of Archimedes and are registered asCTM, and US Registered Trademarks and in ...

Immunomedics Reports Initial Clinical Results With Hpam4 For Pancreatic Cancer Therapy

...11,to ensure an acceptable distribution within the body and radiationdose to the pancreas for intended the...1In-hPAM4showed acceptable distribution within the body and radiation dosageto the pancreas. 90Y-hPAM4 was administrated at 15 mCi/m(2), 20mCi/m(2) or 25 mC...

Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control

...ential method for regulatingmetabolism, decreasing body weight and managing blood glucose. Thedata were pr...e were fed ahigh-fat diet for 15 weeks, with their body weight and food intakemonitored throughout the experiment. The results showed after 15weeks on the d...

Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death

...uid, which leads to swelling and weight gain.Extra body fluid can make some heart problems worse or lead toheart failure. If you have swelling or fluid retention, shortnessof breath or trouble breathing, an unusually rapid increase inweight, or unusual tiredness while taking Avandia, call your doctorright...

Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting

...lif. "These data add significantly to the growing body of evidencesupporting the hypothesis that IPI-504 ...ned tracer molecule is then injectedinto the human body where it is taken up and trapped within thetumor cells. The most common tracer used in oncology for ...

MGI Pharma Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting

...of distribution of Aloxi increased withage-related body weight, as expected. The long half-life (21-37hours) of Aloxi in this pediatric population was consistent withthat in adults. There were no cardiac safety concerns or serioustreatment related adverse events. Dacogen(R) for Injection Study of Respon...

Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab

...se has spread beyond the skin to other parts ofthe body by way of the bloodstream or the lymphatic system(metastatic disease). Melanoma accounts for about three percent ofskin cancer cases, but it causes most skin cancer deaths. TheAmerican Cancer Society estimates that in 2007 there will be 59,940new cas...

MGI Pharma, Inc. Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting

...of distribution of Aloxi increased withage-related body weight, as expected. The long half-life (21-37hours) of Aloxi in this pediatric population was consistent withthat in adults. There were no cardiac safety concerns or serioustreatment related adverse events. Dacogen(R) for Injection Study of Respon...

Caelyx Delays Time to Disease Progression as Maintenance Therapy in Patients with Metastatic Breast Cancer

...illary (underarm) lymph nodes to other areas ofthe body where they continue to grow and multiply. Breast cancerhas the potential to spread to almost any region of the body. Themost common region breast cancer spreads to is bone, followed bylung and liver. About CAELYX CAELYX is a long-circulating pegylat...

Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival

...size of the interferon so itis eliminated from the body more slowly. Pegylation allows foronce-weekly dosing rather than the three-times-weekly dosingrequired for standard interferon. Schering-Plough Corporation is a global science-based health carecompany with leading prescription, consumer and animal he...

8-Year Long-term Data Demonstrate Prolonged Overall Survival and Length of Disease Remission with Bexxar

...:441,2005). "These data contribute to the growing body of evidencesupporting the effectiveness of BEXXAR," said David Moules, VicePresident, Oncology, GlaxoSmithKline. "GSK is proud to be a leadingdeveloper of new medicines, like BEXXAR, for patients battlinglymphoma, and these results support our ongoin...

Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression

...itor - SNRI) and thesefindings support the growing body of evidence that Cipralex(R)offers important treatment advantages over SNRI antidepressantssuch as duloxetine(2-6). Depression is a serious illness that results in significantdisability and is associated with both increased morbidity and therisk of ...

New Data Show Pfizer's Axitinib Prolonged Overall Survival in Advanced Pancreatic Cancer When Combined with Standard of Care Chemotherapy

...zer. "These exciting data contribute toan emerging body of research indicating the benefit that oralselective inhibitors of VEGF receptors, like axitinib, may provideto patients. We have plans to further explore axitinib in advancedpancreatic cancer as part of a Phase III program and are continuingto eval...

Soliris Effective in PNH Patients With History of Aplastic Anemia and Myelodysplastic Syndromes

...n Society of Clinical Oncology (ASCO). "A growing body of evidence shows that all PNH patients have thepotential to realize meaningful improvement with Soliris,regardless of symptoms, history of bone marrow failure, ortransfusion needs prior to treatment," said Leonard Bell, MD, chiefexecutive officer of...

Pharmacyclics Announces Promising Results From Phase 2 Clinical Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung Cancer

...ced stages. Lungcancer frequently spreads to other body parts, including thebrain. Xcytrin in Second-Line Lung Cancer Pharmacyclics is developing Xcytrin as an anti-cancer agent witha novel mechanism of action that is designed to selectivelyconcentrate in tumors and induce apoptosis (programmed cell dea...
Other Contentsgroovegroovegroovetransferasetransferasepericardialpericardiumpericardium
(Date:10/12/2008)...nn and Dsseldorf Universities have discovered an i...esearchers investigated over 500,000 positions in ...ccurs clearly more frequently in bald men than in ...n the November issue of the journal Nature Geneti... London time, doi: 10.1038/ng.228). In 2005, these...
(Date:10/10/2008)...cial Surgery researchers have found that statins m...e suffering from pregnancy complications caused by...tudy in mice. In this autoimmune syndrome, the bod...he main components of cell membranes. This news co... the Journal of Clinical Investigation that is c...
(Date:10/10/2008)...IS Investigators from the Herman B Wells Center f...hool of Medicine are focusing on a family of blood...g the toxic effects of chemotherapy in children an...the development of targeted therapies for leukemia... , The researchers, led by Kristin T. Chun, Ph.D...
(Date:10/10/2008)... Yale scientists have created nanowire sensors co...are both sensitive and specific enough to be used ...ng to a report in Nano Letters . , The sensors ...antigens signatures of bacteria, viruses or cance...ed, they produce acid, and generate a tiny current...
Breaking Biology News(10 mins):Important new hair-loss gene discovered 2Statins may prevent miscarriages 2Statins may prevent miscarriages 3On the trail of a targeted therapy for blood cancers 2Sensitive nanowire disease detectors made by Yale scientists 2Galderma Announces HSR Clearance for Its Proposal to Acquire CollaGenex Pharmaceuticals 14745 1Galderma Announces HSR Clearance for Its Proposal to Acquire CollaGenex Pharmaceuticals 14745 2Galderma Announces HSR Clearance for Its Proposal to Acquire CollaGenex Pharmaceuticals 14745 3Galderma Announces HSR Clearance for Its Proposal to Acquire CollaGenex Pharmaceuticals 14745 4Galderma Announces HSR Clearance for Its Proposal to Acquire CollaGenex Pharmaceuticals 14745 5The Leukemia 26 Lymphoma Society Receives More Than 2436 000 From Regence 14742 1The Leukemia 26 Lymphoma Society Receives More Than 2436 000 From Regence 14742 2Law Offices of Howard G Smith Announces Class Action Lawsuit Against Vertex Pharmaceuticals Incorporated 14739 1GSK Charitable Support Valued at 24564 Million in 2007 14736 1GSK Charitable Support Valued at 24564 Million in 2007 14736 2GSK Charitable Support Valued at 24564 Million in 2007 14736 3
(Date:10/10/2008)... BEDFORD, Mass., Oct. 10 /PRNewswire-FirstCall/...loper, manufacturer and supplier of premium,diagno...ts dedicated to,serving the healthcare needs of wo...uarter and fiscal 2008 operating results on Tuesda...ction with the release, management will,host a con...
(Date:10/10/2008)... PARK CITY, Utah, Oct. 10 /PRNewswire/ -- NuVie... management of Trace Life Sciences Inc.,(Trace), i...cyclotron,production facilities in Denton, Texas. ... Indium-111, Iodine-123 and Thallium-201 used in,m... NuView Chairman and,CEO, stated that "We are conf...
(Date:10/10/2008)... Coach Holly Warlick Teams Up with Legal and Me...rst-Ever Cancer and Careers Seminar in,Knoxville, ...gnition of National,Breast Cancer Awareness Month,... have joined forces with YWCA Knoxville, The Welln...ocate Holly Warlick, University of Tennessee,women...
(Date:10/10/2008)... The Healthcare Technolog...Care , Exton, PA (PRWEB) ...Valley Chapters of the national Healthcare Informa...ned forces to bring regional health information te...onal conference entitled The Healthcare Technology...
Breaking Medicine News(10 mins):Health News:Hologic, Inc. To Release Fourth Quarter and Fiscal 2008 Operating Results on Tuesday, November 11, 2008 2Health News:Local Experts Help Women Living and Working with Cancer Even the Score 2Health News:Local Experts Help Women Living and Working with Cancer Even the Score 3Health News:Local Experts Help Women Living and Working with Cancer Even the Score 4Health News:HIMSS New Jersey and Delaware Valley Chapters Sponsor Regional Conference 2
Other TagsTuraTuraTuraTuraTuraELLEELLEELLEELLEELLEOther Tagsfluorescent 2fluorescent 3progressive 2progressive 3progressive 4progressive 5progressive 6progressive 7progressive 8progressive 9progressive 10historic 2prematurely 2account 2account 3account 4account 5account 6account 7account 8account 9account 10types 2types 3types 4types 5types 6types 7types 8types 9types 10